ZINECARD

This page contains recent news articles, when available, and an overview of ZINECARD but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

ZINECARD (when available)

Pharmacology and use:
Dexrazoxane is a cardioprotective agent for use in conjunction with doxorubicin indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose. For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer

Mechanism Of Action:
The mechanism by which Dexrazoxane exerts its cardioprotective activity is not fully understood. Dexrazoxane is a cyclic derivative of EDTA that readily penetrates cell membranes. Results of laboratory studies suggest that Dexrazoxane is converted intracellularly to a ring-opened chelating agent that interferes with iron-mediated free radical generation thought to be responsible, in part, for anthracycline-induced cardiomyopathy.

News Articles on Dexrazoxane

… 2006 - 71 FR 6081 Referral of ZINECARD (dexrazoxane) and RELPAX ( …  -  Feb 6, 2006
FDA referred the ZINECARD (dexrazoxane) and RELPAX (eletriptan) Written Requests to the Foundation on August 29, 2005, and is publishing this notice of the ... Pay-Per-View - Federal Register 2006 - Loislaw

dexrazoxane TopoTarget Priority Review, USA (cancer therapy toxicity)...  -  Apr 24, 2006
...dexrazoxane, razoxane (+), (S), ICRF 187, NSC 169780, ADR529, ICI 59118, CARDIOXANE, EUCARDION, RAZOXIN, ZINECORE, ZINECARD, ANTRAGARD, TOPOTECT, TOTECT, ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones

你认为中国彩电未�?�能�?�崛起？ - 平�?�世界 - �?��?数�?公社  -  Jul 5, 2007
Bulletin of to defend to higher staff and zinecard capital. Some studies beings is license for most types humansb. The increases were virtually fm an ... sohu.com

Cardiac Toxicity  -  Mar 5, 2007
Dexrazoxane (Zinecard®): This drug has been shown to prevent or reduce the severity of heart damage caused by doxorubicin. [3] Dexrazoxane is thought to ... Cancer Consultants

HemOnc Today Mobile - Home  -  Jan 1, 2008
Dexrazoxane (Zinecard, Pfizer) has been available since 2002 as a cardioprotective agent indicated for reducing cardiomyopathy associated with doxorubicin ... HemOncToday

Press Release: New Guidelines to Raise the Standard of Care for...  -  Feb 5, 2008
Totect is the first and only anthracycline extravasation treatment approved by the U ... including Zinecard) for Totect anthracycline extravasation ... Pay-Per-View - PR Newswire Europe - HighBeam Research

Article: Women undergoing angioplasty for MI at high risk.(Cardiovascu...  -  Aug 15, 2005
Article: Pharmacia receives marketing clearance for ZINECARD(TM) ... Business Wire; May 30, 1995 ; 700+ words ... ... motto "To Life" reflects these goals. ... Pay-Per-View - Family Practice News - HighBeam Research

Brand Names/Synonyms:
ZINECARD is also known by the following brand names and/or synonymsADR-529; CCRIS 1271; Cardioxane; Desrazoxane; Dexrazoxane; Dexrazoxane [Usan:Ban:Inn]; Dexrazoxano [Inn-Spanish]; Dexrazoxanum [Inn-Latin]; Dextrorazoxane; Dyzoxane; Eucardion; ICRF 159; ICRF-159; ICRF-187; Razoxana [Inn-Spanish]; Razoxane; Razoxane [Ban:Inn]; Razoxanum [Inn-Latin]; Razoxin; Tepirone; Troxozone; Zinecard

Drug Category:
ZINECARD is categorized under the following by the FDA: Immunosuppressive Agents; Chelating Agents; Cardiovascular Agents; Antineoplastic Agents; ATC:V03AF02

Dosage Forms:
LIQUID;POWDER FOR SOLUTION

Absorption:
IV administration results in complete bioavailability.

Interactions:
[an error occurred while processing this directive]

Chemical IUPAC Name:
4-[2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.